Skip to main content

tunlucabtagene autoleucel

Generic: Tunlucabtagene Autoleucel

tunlucabtagene autoleucel: 2 clinical trials tracked.

tunlucabtagene autoleucel evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about tunlucabtagene autoleucel, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Multiple Myeloma

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Phase 1b Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Newly Diagnosed Multiple Myeloma

NCT07333261Registry updated 2026-02-13·Phase 1
Recruiting

Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Interventionalopen25 targetStarted 2026-02Completion 2041-121 site · United StatesSusan Bal

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06153251Registry updated 2026-03-18·Phase 1
Recruiting

Primary endpoint: Number of participants with treatment-emergent adverse events (AEs)

Interventionalopen187 targetStarted 2024-01Completion 2030-0519 sites · France, Germany, Spain, United StatesJuno Therapeutics, Inc., a Bristol-Myers Squibb Company